Lake Street downgraded Optinose (OPTN) to Hold from Buy with a price target of $9, down from $17, after Paratek Pharmaceuticals announced it will be acquiring OptiNose for up to $330M, or $14 per share. Shareholders will be granted contingent value rights worth up to $5 per share, notes the analyst, who expects no additional bids and for the deal to close in mid-2025.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPTN:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue